Pharmaceutical Care for Drug-induced Liver Injury in a Patient with Idiopathic Thrombocytopenic Purpura Complicated with Pulmonary Thromboembolism

doi:10.19803/j.1672-8629.2021.01.19

Abstract

Abstract: Objective To study the importance of pharmaceutical care through a clinical pharmacist involved in the treatment of a patient with idiopathic thrombocytopenic purpura,pulmonary thromboembolism,and drug-induced liver injury.Methods A clinical pharmacist assisted the physician in selecting an anticoagulant and its dose,adjusting the hepatoprotective drug,and identifying the drug that might have caused liver damage in a patient with primary thrombocytopenia and pulmonary thromboembolism so that the physician was able to make an individualized treatment plan.Results After treatment,the patient's liver functions basically returned to normal,and the anticoagulation medication was safe and effective.Conclusion Clinical pharmacists' participation in pharmaceutical care can improve the efficacy of medication and ensure the safety of patients.

Key words: idiopathic thrombocytopenic purpura, pulmonary thromboembolism, drug-induced liver injury, pharmaceutical care

CLC Number:

R969.3

WANG Yingkai, CUI Xiangli, LIU Lihong. Pharmaceutical Care for Drug-induced Liver Injury in a Patient with Idiopathic Thrombocytopenic Purpura Complicated with Pulmonary Thromboembolism[J]. Chinese Journal of Pharmacovigilance, 2021, 18(1): 90-93.

References

[1] Maschmeyer G,Helweg-Larsen J,Pagano L,et al.ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients[J].J Antimicrob Chemother,2016 ,71(9):2405-2413.
[2] Lane MA,Devine ST,McDonald JR.High‐risk antimicrobial prescriptions among ambulatory patients on warfarin[J].J Clin Pharm Ther,2012 ,37(2):157-160.
[3] Anderson Jr FA,Spencer FA.Risk factors for venous thromboem-bolism[J].Circulation,2003,107(23 Suppl 1):9-16.
[4] Saleh MN,Bussel JB,Cheng G,et al.Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia:results of the long-term,open-label EXTEND study[J].Blood,2013,121(3):537-545.
[5] Kim KJ,Baek IW,Yoon CH,et al.Thrombotic risk in patients with immune thrombocytopenia and its association with antiphospholipid antibodies[J].Br J Haematol,2013 ,161(5):706-714.
[6] Chinese Medical Association Respiratory Diseases Pulmonary Embolism and Pulmonary Vascular Diseases Group,Chinese Medical Association Respiratory Physician Branch Pulmonary Embolism and Pulmonary Bascular Disease Working Committee,National Pulmonary Embolism and Pulmonary Vascular Disease Prevention and Treatment Group.The guideline of pulmonary thrombosis diagnosis and treatment[J].Natl Med J China(中华医学杂志),2018,98(14):1060-1087.
[7] Wei J,Jin H,Chai YF,et al.CYP2C9 and VKORC1 gene detection to guide the clinical study of individualized warfarin anticoagulation therapy in patients with acute pulmonary thromboembolism[J/OL].Chin J Crit Care Med(中华重症医学),Electron Ed,2016,9(2):91-95.
[8] Yu JJ,Kuang Y,Wang H,et al.Research status of the interaction between warfarin and antibacterial drugs and its mechanism[J].Chin J Clin Pharmacol(中国临床药理学杂志),2016,32(24):2319-2322,2336.
[9] Hosaka K,Saito S,Ishii T,et al.Safety of fondaparinux versus enoxaparin after TKA in Japanese patients[J].Orthopedics,2013,36(4):e428-e433.
[10] Gu YL,Ge WH.Yu F.Research progress on the interaction between warfarin and antibacterial drugs[J].Chin J Hosp Pharm(中国医院药学杂志),2013,33(20):1708-1710.
[11] Drug-induced liver disease group of the Chinese Society of Hepatology.Guidelines for the diagnosis and treatment of drug-induced liver injury[J].J Clin Hepatol,2017,20(2):1-18
[12] Zhang Y,You PC,Zheng QS.Investigation and analysis of 115 cases of warfarin clinical application[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2011,8(9):524-527.
[13] Zhao YQ,Gao J,Xie C.A case of pharmaceutical care of a patient with atrial fibrillation taking warfarin anticoagulant therapy[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2011,8(10):632-633.

[1]	WANG Xin, SHI Leilei, ZHANG Yuhan, XIE Yundong, LIU Jiping. The role of MRPs transporters in drug-induced liver injury [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 229-234.
[2]	BUCHANAN James. Assessment of drug-induced liver injury via nR modified Hy’s law and P_ALT [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 117-120.
[3]	ZHANG Xialan, YUAN Jing, WU Bin, QIN Yuanyuan. Medications of apatinib mesylate in patients with malignant tumors [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 927-932.
[4]	WANG Ran, LI Yifan, LIU Xiaoyan, FENG Xin. One case of pharmaceutical care of drug exposure during pregnancy [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 933-934.
[5]	LIU Jing, XIA Liang, ZHANG Shijie. Pharmaceutical care of a patient with acute pancreatitis complicated with multiple drug allergy undergoing drug stimulation test [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 822-824.
[6]	WANG Ran, FENG Xin, DU Boran. Advances in risk assessment and pharmaceutical care of pregnancy medication exposure during perinatal period [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 836-840.
[7]	CHEN Chongze, LI Jie, KUANG Lian, TAN Xuewen, LIU Minhui, LIU Xi, ZHENG Yanchai, JIN Hongtao. Characterization of adverse reactions associated with drug-induced liver injury in 448 inpatients [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 697-704.
[8]	LI Rongrong, LI Meng, GOU Yue, LUO Qiong, LYU Hua, SUN Xin, LIU Chenghai. Clinical characteristics and risk factors of 113 cases of anti-neoplastic drug-induced liver injury [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 505-510.
[9]	YAO Keyu, ZHANG Shuqi, JIN Rui, LIU Lihong, ZHU Yan. Comparative study on data set of drug-induced liver injury [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 568-573.
[10]	HUO Peiqiong, ZHENG Peng, SU Zhenhao. Pharmacovigilance in retail pharmacies for special or major diseases [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 428-432.
[11]	CHEN Chao, ZHU Lan, LIU Lihong, HAN Jiayin, ZHU Yan. Characteristics of Psoralea corylifolia induced liver injury [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 449-453.
[12]	YANG Yan, ZHOU Dexi, WU Xinli, XUE Shuya, DING Haihua, ZHANG Quan, ZHANG Yunling. Eighty-four cases of adverse drug reactions caused by novel anti-tumor drugs [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 334-338.
[13]	WANG Yu, HUANG Jingyi, HOU Lixin, LI Shuang, CUI Yongkang, HUANG Lanwei. Humoral immune characteristics of peripheral blood of CAP patients with antibiotic-associated DILI [J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 132-135.
[14]	YAO Xin, GE Qiuge, LI Yamin, WANG Yifan, LI Yuanyuan, LIU Zhiqiang. Adverse drug reactions caused by new anti-tumor drugs from 2018 to 2022 in one hospital [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1273-1278.
[15]	ZHENG Jinfeng, WANG Jinghong. Pharmaceutical care of one case of malignant arrhythmia induced by multidrug combination [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1279-1281.